English

Monte Rosa Therapeutics, Inc.

EDGAR

GLUE Quarterly report (10-Q) · filed 2026-08-06

28 filing records in this dataset, filed from 2021-06-04 to 2026-08-06. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Cash and cash equivalents: 90.1 million USD 2026-06-30 Source
Exact value

90104000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 85.2 million shares 2026-06-30 Source
Exact value

85226427 shares

Reported share-count change

38.09% · 23.5 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

61717349 shares · 2025-06-30· Source
85226427 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-161 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -27081000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -38600000 USD · 2025-01-01 – 2025-12-31 Source
Net income: 7509000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -44503000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -43397000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-24.1 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: 20216000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -80212000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -22798000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: 20216000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -37369000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -81483000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -37369000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

8.01 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 3933000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 3282000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 4700000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 3933000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 1868000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 6591000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 1868000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-32.1 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: 20216000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -80212000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -22798000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: 20216000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -37369000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -81483000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -37369000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 3933000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 3282000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 4700000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 3933000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 1868000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 6591000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 1868000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-06.

Financial data available through: 2025-12-31.

Coverage by financial measure

revenue: No compatible figures in this window
Operating income: 6 of 11 periods available· newest 2025-12-31
Net income: 6 of 11 periods available· newest 2025-12-31
Operating cash flow: 6 of 11 periods available· newest 2025-12-31
Capital expenditure: 6 of 11 periods available· newest 2025-12-31
Total assets: 6 of 11 periods available· newest 2025-12-31
Total liabilities: 6 of 11 periods available· newest 2025-12-31
Current assets: 6 of 11 periods available· newest 2025-12-31
Current liabilities: 6 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 6 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
+USD 34.1 million

Prior period

−USD 72.7 million

2024-01-01 – 2024-12-31
Current period

−USD 38.6 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-38600000 − -72700000 = 34100000 USD

-72700000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-38600000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Monte Rosa Therapeutics, Inc. · 2025-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Year-over-year change in Net income: 34100000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -38600000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000119312526336711/glue-20260630.htm#1063217 Filing: 000119312526336711 Input fundies:NetIncome: -72700000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000119312526109360/glue-20251231.htm#3978942 Filing: 000119312526109360
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
-154.3%

Prior period

USD 42 million

2024-01-01 – 2024-12-31
Current period

−USD 22.8 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-22798000 − 41996000 = -64794000 USD

41996000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-22798000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Monte Rosa Therapeutics, Inc. · 2025-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Year-over-year change in Operating cash flow: -64794000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -22798000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000119312526109360/glue-20251231.htm#2481448 Filing: 000119312526109360 Input fundies:OperatingCashFlow: 41996000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000119312526109360/glue-20251231.htm#2483332 Filing: 000119312526109360
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+17.9%

Prior period

USD 3.99 million

2024-01-01 – 2024-12-31
Current period

USD 4.7 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

4700000 − 3988000 = 712000 USD

3988000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
4700000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Monte Rosa Therapeutics, Inc. · 2025-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Year-over-year change in Capital expenditure: 712000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 4700000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000119312526109360/glue-20251231.htm#2488395 Filing: 000119312526109360 Input fundies:CapitalExpenditure: 3988000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000119312526109360/glue-20251231.htm#2490254 Filing: 000119312526109360
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

Revenue is not reported for this company, so its costs cannot be shown as a share of it.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Not enough comparable data to show this history.

Values and sources

Revenue values and source evidence
Period	Series	Value	Source evidence

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.

Values and sources

Operating cash flow values and source evidence
Period	Series	Value	Source evidence

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	−USD 35.88 million Exact value Exact value: -35879000 USD 2020-01-01 – 2020-12-31: -35879000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Monte Rosa Therapeutics, Inc. · 2020-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Net Income: -35879000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -35879000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000095017022004927/glue-20211231.htm#3145009 Filing: 000095017022004927 The citation records this snapshot. The page link may show a newer release later.	−USD 23.05 million Exact value Exact value: -23053000 USD 2020-01-01 – 2020-12-31: -23053000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Monte Rosa Therapeutics, Inc. · 2020-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Operating Cash Flow: -23053000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23053000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000095017022004927/glue-20211231.htm#2192657 Filing: 000095017022004927 The citation records this snapshot. The page link may show a newer release later.	USD 3.39 million Exact value Exact value: 3389000 USD 2020-01-01 – 2020-12-31: 3389000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Monte Rosa Therapeutics, Inc. · 2020-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Capital Expenditure: 3389000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3389000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000095017022004927/glue-20211231.htm#2199653 Filing: 000095017022004927 The citation records this snapshot. The page link may show a newer release later.	−USD 26.44 million Calculation and evidence -23053000 − 3389000 USD Exact free cash flow: -26442000 USD 2020-01-01 – 2020-12-31: -23053000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 3389000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Monte Rosa Therapeutics, Inc. · 2020-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Free cash flow: -26442000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -23053000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000095017022004927/glue-20211231.htm#2192657 Filing: 000095017022004927 Input fundies:CapitalExpenditure: 3389000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000095017022004927/glue-20211231.htm#2199653 Filing: 000095017022004927 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 73.96 million Exact value Exact value: -73958000 USD 2021-01-01 – 2021-12-31: -73958000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Monte Rosa Therapeutics, Inc. · 2021-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Net Income: -73958000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -73958000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000095017023008440/glue-20221231.htm#3671202 Filing: 000095017023008440 The citation records this snapshot. The page link may show a newer release later.	−USD 59.36 million Exact value Exact value: -59363000 USD 2021-01-01 – 2021-12-31: -59363000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Monte Rosa Therapeutics, Inc. · 2021-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Operating Cash Flow: -59363000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -59363000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000095017023008440/glue-20221231.htm#2471168 Filing: 000095017023008440 The citation records this snapshot. The page link may show a newer release later.	USD 9.73 million Exact value Exact value: 9732000 USD 2021-01-01 – 2021-12-31: 9732000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Monte Rosa Therapeutics, Inc. · 2021-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Capital Expenditure: 9732000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9732000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000095017023008440/glue-20221231.htm#2479135 Filing: 000095017023008440 The citation records this snapshot. The page link may show a newer release later.	−USD 69.1 million Calculation and evidence -59363000 − 9732000 USD Exact free cash flow: -69095000 USD 2021-01-01 – 2021-12-31: -59363000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 9732000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Monte Rosa Therapeutics, Inc. · 2021-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Free cash flow: -69095000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -59363000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000095017023008440/glue-20221231.htm#2471168 Filing: 000095017023008440 Input fundies:CapitalExpenditure: 9732000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000095017023008440/glue-20221231.htm#2479135 Filing: 000095017023008440 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 108.5 million Exact value Exact value: -108501000 USD 2022-01-01 – 2022-12-31: -108501000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Monte Rosa Therapeutics, Inc. · 2022-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Net Income: -108501000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -108501000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000095017024031150/glue-20231231.htm#2869951 Filing: 000095017024031150 The citation records this snapshot. The page link may show a newer release later.	−USD 92.47 million Exact value Exact value: -92466000 USD 2022-01-01 – 2022-12-31: -92466000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Monte Rosa Therapeutics, Inc. · 2022-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Operating Cash Flow: -92466000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -92466000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000095017024031150/glue-20231231.htm#1962576 Filing: 000095017024031150 The citation records this snapshot. The page link may show a newer release later.	USD 12.91 million Exact value Exact value: 12911000 USD 2022-01-01 – 2022-12-31: 12911000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Monte Rosa Therapeutics, Inc. · 2022-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Capital Expenditure: 12911000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 12911000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000095017024031150/glue-20231231.htm#1967859 Filing: 000095017024031150 The citation records this snapshot. The page link may show a newer release later.	−USD 105.38 million Calculation and evidence -92466000 − 12911000 USD Exact free cash flow: -105377000 USD 2022-01-01 – 2022-12-31: -92466000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 12911000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Monte Rosa Therapeutics, Inc. · 2022-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Free cash flow: -105377000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -92466000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000095017024031150/glue-20231231.htm#1962576 Filing: 000095017024031150 Input fundies:CapitalExpenditure: 12911000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000095017024031150/glue-20231231.htm#1967859 Filing: 000095017024031150 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 135.35 million Exact value Exact value: -135352000 USD 2023-01-01 – 2023-12-31: -135352000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Monte Rosa Therapeutics, Inc. · 2023-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Net Income: -135352000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -135352000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000095017025042344/glue-20241231.htm#4165103 Filing: 000095017025042344 The citation records this snapshot. The page link may show a newer release later.	−USD 43.8 million Exact value Exact value: -43802000 USD 2023-01-01 – 2023-12-31: -43802000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Monte Rosa Therapeutics, Inc. · 2023-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Operating Cash Flow: -43802000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -43802000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000095017025042344/glue-20241231.htm#2944804 Filing: 000095017025042344 The citation records this snapshot. The page link may show a newer release later.	USD 19.04 million Exact value Exact value: 19041000 USD 2023-01-01 – 2023-12-31: 19041000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Monte Rosa Therapeutics, Inc. · 2023-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Capital Expenditure: 19041000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 19041000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000095017025042344/glue-20241231.htm#2951354 Filing: 000095017025042344 The citation records this snapshot. The page link may show a newer release later.	−USD 62.84 million Calculation and evidence -43802000 − 19041000 USD Exact free cash flow: -62843000 USD 2023-01-01 – 2023-12-31: -43802000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 19041000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Monte Rosa Therapeutics, Inc. · 2023-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Free cash flow: -62843000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -43802000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000095017025042344/glue-20241231.htm#2944804 Filing: 000095017025042344 Input fundies:CapitalExpenditure: 19041000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000095017025042344/glue-20241231.htm#2951354 Filing: 000095017025042344 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 72.7 million Exact value Exact value: -72700000 USD 2024-01-01 – 2024-12-31: -72700000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Monte Rosa Therapeutics, Inc. · 2024-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Net Income: -72700000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -72700000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000119312526109360/glue-20251231.htm#3978942 Filing: 000119312526109360 The citation records this snapshot. The page link may show a newer release later.	USD 42 million Exact value Exact value: 41996000 USD 2024-01-01 – 2024-12-31: 41996000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Monte Rosa Therapeutics, Inc. · 2024-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Operating Cash Flow: 41996000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 41996000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000119312526109360/glue-20251231.htm#2483332 Filing: 000119312526109360 The citation records this snapshot. The page link may show a newer release later.	USD 3.99 million Exact value Exact value: 3988000 USD 2024-01-01 – 2024-12-31: 3988000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Monte Rosa Therapeutics, Inc. · 2024-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Capital Expenditure: 3988000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3988000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000119312526109360/glue-20251231.htm#2490254 Filing: 000119312526109360 The citation records this snapshot. The page link may show a newer release later.	USD 38.01 million Calculation and evidence 41996000 − 3988000 USD Exact free cash flow: 38008000 USD 2024-01-01 – 2024-12-31: 41996000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 3988000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Monte Rosa Therapeutics, Inc. · 2024-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Free cash flow: 38008000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 41996000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000119312526109360/glue-20251231.htm#2483332 Filing: 000119312526109360 Input fundies:CapitalExpenditure: 3988000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000119312526109360/glue-20251231.htm#2490254 Filing: 000119312526109360 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 38.6 million Exact value Exact value: -38600000 USD 2025-01-01 – 2025-12-31: -38600000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Monte Rosa Therapeutics, Inc. · 2025-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Net Income: -38600000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -38600000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000119312526336711/glue-20260630.htm#1063217 Filing: 000119312526336711 The citation records this snapshot. The page link may show a newer release later.	−USD 22.8 million Exact value Exact value: -22798000 USD 2025-01-01 – 2025-12-31: -22798000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Monte Rosa Therapeutics, Inc. · 2025-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Operating Cash Flow: -22798000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -22798000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000119312526109360/glue-20251231.htm#2481448 Filing: 000119312526109360 The citation records this snapshot. The page link may show a newer release later.	USD 4.7 million Exact value Exact value: 4700000 USD 2025-01-01 – 2025-12-31: 4700000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Monte Rosa Therapeutics, Inc. · 2025-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Capital Expenditure: 4700000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4700000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000119312526109360/glue-20251231.htm#2488395 Filing: 000119312526109360 The citation records this snapshot. The page link may show a newer release later.	−USD 27.5 million Calculation and evidence -22798000 − 4700000 USD Exact free cash flow: -27498000 USD 2025-01-01 – 2025-12-31: -22798000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 4700000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Monte Rosa Therapeutics, Inc. · 2025-12-31 Monte Rosa Therapeutics, Inc. (edgar:1826457) Free cash flow: -27498000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1826457?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -22798000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000119312526109360/glue-20251231.htm#2481448 Filing: 000119312526109360 Input fundies:CapitalExpenditure: 4700000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1826457/000119312526109360/glue-20251231.htm#2488395 Filing: 000119312526109360 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

28 filings · 1,298 latest values · 1,298 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001826457, 1826457, GLUE, edgar:1826457

Also known as MONTE ROSA THERAPEUTICS, INC., Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc.

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

Growth

Profit and cash

Balance sheet

Cash generation